22302-59-6Relevant academic research and scientific papers
Cycloalkyl thienopyrimidinone compounds as well as preparation method and application thereof
-
Paragraph 0062; 0064-0067, (2020/07/12)
The invention relates to a parent nucleus compound containing cycloalkyl[4,5]thieno[2,3-d]pyrimidin-4 (3H)-one, and the parent nucleus compound has the following structure shown in the specification,wherein R1, X, m and n are defined in the specification.
Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors
Zhu, Kongkai,Song, Jia-Li,Tao, Hong-Rui,Cheng, Zhi-Qiang,Jiang, Cheng-Shi,Zhang, Hua
supporting information, p. 3693 - 3699 (2018/10/24)
Protein arginine methyltransferase 5 (PRMT5) is an epigenetics related enzyme that has been validated as a promising therapeutic target for human cancer. Up to now, two small molecule PRMT5 inhibitors has been put into phase I clinical trial. In the prese
Triamine derivatives and their acid-addition salts
-
, (2008/06/13)
A triamine derivative of the formula (I) ψψ ψwherein Ar1 and Ary are carbocyclic or heterocyclic single ring or fused ring aromatic groups, R1, Ry and R3 are hydrogen, lower alkyl, aryl aryl-alkyl, aryl-alkyloxycarbonyl, alkyloxycarbonyl or acyl, and A1 and Ay are lower alkylene groups optionally substituted by oxo, exhibits a high N-methyl-D-aspartic acid (NMDA) receptor antagonistic effect and are therefore useful as a medicine for nerve degeneration diseases.ψ
